Impact of Cusp-Overlap View for TAVR with Self-Expandable Valves on 30-Day Conduction Disturbances

Table 2

Procedural characteristic and 30-day outcomes.

	CON group, n = 101 (%)	COVL group n = 156 (%)
Femoral access	101	156	—
Percutaneous closure	100 (99)	156	0.21
THV evolute R/PRO™
23	3 (3)	7 (4.5)	0.90
26	18 (17.8)	39 (25)	0.17
29	57 (56.4)	75 (48.1)	0.14
34	22 (21.8)	35 (22.4)	0.85
Predilatation	58 (57.4)	86 (55.1)	0.18
Postdilatation	25 (24.5)	34 (21.8)	0.58
Valve pop-out after delivery	—	1 (0.64)	0.42
30-day outcomes
Death	5 (4.9)	4 (2.6)	0.3
AMI	—	1 (0.6)	0.42−
Any stroke	—	1	1
Acute coronary occlusion (stent thrombosis)	—	1 (0.6)	0.42
Major bleeding	2 (2)	1 (0.6)	0.32
Vascular complication	2 (2)	6 (3.8)	0.40
Moderate aortic regurgitation	2 (2)	4 (2.5)	0.76
Severe aortic regurgitation	—	—	—
PPMI	18 (17.8)	10 (6.4)	0.004
New-onset LBBB	13 (12.9)	9 (5.8)	0.05
Hospital stay (days)	2.9 ± 1.1	2.7 ± 1.1	0.30